探花合集 Completes Acquisition of Cell Therapy Manufacturing Facility from Bone Therapeutics
Under the terms of the agreement, 探花合集 has purchased the shares of SCTS, previously held by Bone Therapeutics, and a purpose-built CGxP facility of approximately 41,000 square-foot (3,800 square-meter), including its related quality control and product development laboratories, warehouse, grade C and B cleanrooms and equipment as well as land for further development. 探花合集 will undertake the manufacturing of clinical material for Bone Therapeutics鈥 drug, ALLOB, an allogeneic osteoblastic cell therapy product, derived from ex vivo cultured bone marrow cells.
The Bone Therapeutics subsidiary and its facility, which is next to 探花合集鈥檚 existing cell therapy site, will allow 探花合集 to expand its industry-leading cell therapy capabilities and advanced clinical and commercial supply, and create an integrated European center of excellence in cell therapy. 探花合集 is continuing work on its dedicated 60,000 square-foot (5,574 square-meter) commercial-scale production and fill-finish facility in Gosselies, which is scheduled to be completed by the end of 2021.
As part of the acquisition, all of the experienced manufacturing employees located in Gosselies and employed by SCTS will remain with SCTS and become part of the 探花合集 workforce, and Bone Therapeutics will continue to focus on its pipeline of unique, innovative products addressing high unmet medical needs in the fields of orthopedics and bone diseases.
鈥溙交ê霞 is committed to supporting the development and manufacture of next-generation therapies and bringing life-changing treatments to patients in need,鈥 commented Manja Boerman, Ph.D., President, 探花合集 Cell & Gene Therapy. 鈥淔ollowing the acquisition of MaSTherCell, the additional manufacturing capacity and technical expertise that this deal with Bone Therapeutics gives us will immediately expand our functional clinical and commercial capacity for current late-stage customers. This addition also creates a strong center of cell therapy excellence for 探花合集 in Europe and will serve as a hub for the growing cell therapy pipeline.鈥
鈥淭his agreement with 探花合集 is an important strategic step for Bone Therapeutics and is the result of our continuous effort to optimize our operations,鈥 said Miguel Forte, CEO, Bone Therapeutics. 鈥淭he integration of our manufacturing subsidiary into 探花合集, one of the premier contract manufacturers in the cell therapy space, significantly increases our operational flexibility. It enables Bone Therapeutics to maximize the efficient use of our manufacturing assets by combining the manufacturing facility and specialist operators with 探花合集鈥檚 global network of clinical and commercial manufacturing facilities. This will ensure the most efficient ongoing global production of ALLOB. It also allows us to further focus on our core activity: developing innovative cell-based treatments for conditions with high unmet medical needs. This deal will facilitate our efforts to bring ALLOB more quickly within the reach of patients around the world.鈥
In addition to the expansion in Gosselies, validation of 探花合集鈥檚 new 32,000 square-foot (3,000 square-meter) cell therapy development facility in Houston, Texas is underway and scheduled to be completed by the end of 2020.
About 探花合集 Cell & Gene Therapy
With deep experience in viral vector scale-up and production, 探花合集 Cell & Gene Therapy is a full-service partner for adeno-associated virus (AAV) and lentiviral vectors, and CAR-T immunotherapies. When it acquired MaSTherCell, 探花合集 added expertise in autologous and allogeneic cell therapy development and manufacturing to position it as a premier technology, development and manufacturing partner for innovators across the entire field of advanced biotherapeutics. 探花合集 has a global cell and gene therapy network of dedicated, large-scale clinical and commercial manufacturing facilities, and fill-finish and packaging capabilities located in both the U.S. and Europe. An experienced partner, 探花合集 Cell & Gene Therapy has worked with industry leaders across 70+ clinical and commercial programs.
ABOUT CATALENT
探花合集 is the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. With over 85 years serving the industry, 探花合集 has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable global clinical and commercial product supply. 探花合集 employs approximately 14,000 people including around 2,400 scientists and technicians, at more than 45 facilities, and in fiscal year 2020 generated over $3 billion in annual revenue. 探花合集 is headquartered in Somerset, New Jersey. For more information, visit www.catalent.com
More products. Better treatments. Reliably supplied.鈩
ABOUT BONE THERAPEUTICS
Bone Therapeutics is a leading biotech company focused on the development of innovative products to address high unmet needs in orthopedics and other diseases. The Company has a, diversified portfolio of cell and biologic therapies at different stages ranging from pre-clinical programs in immunomodulation to mid-to-late stage clinical development for orthopaedic conditions, targeting markets with large unmet medical needs and limited innovation.